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Abstract: Inﬂammation is increasingly regarded as a key
process underlying metabolic diseases in obese individuals. In
particular, obese adipose tissue shows features characteristic
of active local inﬂammation. At present, however, little is
known about the sequence of events that comprises the inﬂam-
matory cascade or the mechanism by which inﬂammation
develops. We found that large numbers of CD8(+) effector T cells
inﬁltrated obese epididymal adipose tissue in mice fed a high-
fat diet, whereas the numbers of CD4(+) helper and regulatory
T cells were diminished. The inﬁltration by CD8(+) T cells pre-
ceded the accumulation of macrophages, and immunological
and genetic depletion of CD8(+) T cells lowered macrophage
inﬁltration and adipose tissue inﬂammation and ameliorated
systemic insulin resistance. Conversely, adoptive transfer of
CD8(+) T cells to CD8-deﬁcient mice aggravated adipose inﬂam-
mation. Coculture and other in vitro experiments revealed a
vicious cycle of interactions between CD8(+) T cells, macro-
phages and adipose tissue. Our ﬁndings suggest that obese adi-
pose tissue activates CD8(+) T cells, which, in turn, promote the
recruitment and activation of macrophages in this tissue. These
results support the notion that CD8(+) T cells have an essential
role in the initiation and propagation of adipose inﬂammation.
© 2009 European Association for the Study of the Liver. Pub-
lished by Elsevier B.V. All rights reserved.
Non-alcoholic steatohepatitis (NASH) is rapidly becoming the
leading cause of liver-related morbidity and mortality, largely in
afﬂuent societies. NASH may be present in 10–25% of patients
with hepatic steatosis due to non-alcoholic fatty liver disease
(NAFLD), a condition found in the majority of obese individuals
(BMIP 30 [1]). With obesity rates of 30% in the US, and rising
numbers in almost all countries of the world, prevention and
treatment of NAFLD and especially NASH are urgently needed.Journal of Hepatology 20
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E-mail address: dschuppa@bidmc.harvard.edu (D. Schuppan).NASH is considered the hepatic manifestation of a key feature
of the metabolic syndrome, i.e., insulin resistance in conjunction
with visceral adipose tissue inﬂammation [2]. In contrast, an
increase in peripheral fat alone, i.e., white adipose tissue, is not
associated with the metabolic syndrome or NASH. Thus, the insu-
lin sensitizer Pioglitazone improves insulin sensitivity, fatty liver,
and NASH, despite overall weight gain, due to redistribution of
lipids from central stores to the peripheral (white) adipose tissue
[3].
Chronic, low-grade inﬂammation is now considered to play a
pivotal role in the development of metabolic syndrome in obesity
[2]. In the August issue of Nature Medicine, three studies
addressed different but related aspects of a previously unrecog-
nized pathogenetic role of adaptive (T cell mediated) immunity
in obesity-induced inﬂammation and insulin resistance in mice.
Nishimura et al. [4] analyzed the dynamics of the inﬂammatory
inﬁltrate in the visceral (epididymal) fat of C57Bl/6 mice with
diet-induced obesity. They found that CD8+ T cells were recruited
several weeks before the appearance of adipose tissue-associated
macrophages (ATM), which are the hallmark and effectors of adi-
pose tissue inﬂammation. Both antibody-mediated and genetic
elimination of CD8+ T cells disrupted the vicious circle of adipose
tissue inﬂammation, ATM recruitment and insulin resistance
(Fig. 1), though mice continued to consume the high-fat diet
and became obese. In the same volume, Winer et al. [5] and
Feuerer et al. [6] conﬁrmed an increase in the CD8+ to CD4+ T cell
ratio in mice with diet-induced obesity. Moreover, both studies
report (visceral) adipose tissue-restricted T cell receptor (TCR)
rearrangements and an (oligo)-clonal CD8+ T cell expansion,
pointing to the existence of yet unidentiﬁed ‘‘obesity” neoanti-
gens. Finally, CD4+ Foxp3+ regulatory T cells and CD4+ Th2 T cells
suppressed the proinﬂammatory CD8+ T cell response and pre-
vented insulin resistance [6]. These groundbreaking studies are
paving the way for rapid changes in our understanding of the
metabolic syndrome, with direct implications on NASH
pathogenesis.
In obesity, fat-laden hepatocytes and adipocytes share com-
mon features, such as storage of excess energy and important
endocrine functions; physiological functions of both cell types
are severely affected by obesity-related inﬂammation. Steatohep-
atitis in NASH is tightly linked to visceral adipose tissue inﬂam-
mation in the context of the metabolic syndrome and may
share common pathogenetic mechanisms. In addition, the liver
plays a central role in the regulation of insulin sensitivity,
because lack of insulin signaling in the liver alone was shown
to be sufﬁcient to cause systemic insulin resistance in mice [7].10 vol. 52 j 130–132
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Fig. 1. The study by Nishimura et al. [4] proposes a vicious circle between adipocytes, CD8+ T cells, and adipose tissue macrophages. Hypothetical implications for the
immunology of steatohepatitis is illustrated.
JOURNAL OF HEPATOLOGYSince the discussed papers demonstrate that adaptive (antigen
restricted T cell) immunity is a central trigger (CD8+ T cells) or
suppressor (CD4+ regulatory or Th2 T cells) of the metabolic syn-
drome, the conventional view of NASH pathogenesis as fatty liver
which suffers a ‘‘second (or third) hit” speciﬁc to the liver (such
as certain drugs, genetic predisposition related to oxidative stress
or insulin sensitivity, primary iron overload, or infection with the
hepatitis B or C virus) may have to be broadened. In light of the
novel data it cannot be excluded that reduction in hepatic inﬂam-
mation in NASH patients treated with the glitazones might be
attributable to inhibition of inﬂammatory T cells [8] rather than
their insulin-sensitizing properties. These novel studies provide
a framework for new research into the immune-pathogenesis of
NASH (Fig. 1), which may ﬁnally lead to novel T cell-directed
therapies for steatohepatitis.
Clearly, identiﬁcation of the putative visceral adipose tissue
neoantigen(s) and the relevant antigen-presenting cell(s) become
the next challenges in the obesity ﬁeld and could lead to ground-
breaking discoveries and novel therapies. The potential impact of
these groundbreaking developments on the Hepatology ﬁeld is
indeed hard to overestimate. Clinical and experimental studies
exploring the role of adaptive immunity in NASH pathogenesis
are urgently needed. The following questions remain to be
addressed:Journal of Hepatology 201(1) What is the nature and function of T cells in NASH liver
biopsies, in visceral adipose tissue of patients with NASH,
and in small animal models of NASH? While the T cell
presence and involvement in NASH remains completely
unexplored, inﬂammatory macrophages inﬁltrating the
liver have already been identiﬁed as contributors to
human [9] and rodent steatohepatitis [10].
(2) Is there homing to the liver of the same CD8(+) T cells that
are activated in the visceral adipose tissue, causing hepatic
macrophage recruitment, with subsequent low-grade
inﬂammation and NASH? Of note, a pathological role of
CD8+ T cells has been suggested earlier in hepatic inﬂam-
mation and ﬁbrogenesis in mice [11].
(3) Is there a similarity in TCR rearrangement in the visceral
adipose tissue and the liver of NASH patients (and of NASH
animal models), which would implicate common neoanti-
gens in the adipose tissue and the steatotic liver?
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